Royal Bank of Canada’s Albireo Pharma Inc ALBO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-2,397
Closed -$51K 7784
2022
Q4
$51K Buy
2,397
+1,916
+398% +$40.5K ﹤0.01% 5872
2022
Q3
$10K Buy
481
+351
+270% +$7.26K ﹤0.01% 6445
2022
Q2
$3K Sell
130
-906
-87% -$23.9K ﹤0.01% 6896
2022
Q1
$31K Sell
1,036
-2,714
-72% -$79.5K ﹤0.01% 6372
2021
Q4
$87K Buy
3,750
+2,305
+160% +$61.3K ﹤0.01% 6040
2021
Q3
$45K Buy
1,445
+190
+15% +$5.88K ﹤0.01% 6230
2021
Q2
$45K Buy
1,255
+103
+9% +$3.35K ﹤0.01% 6116
2021
Q1
$41K Buy
1,152
+90
+8% +$3.32K ﹤0.01% 6014
2020
Q4
$40K Buy
1,062
+555
+109% +$20.2K ﹤0.01% 5755
2020
Q3
$17K Sell
507
-122
-19% -$3.55K ﹤0.01% 5764
2020
Q2
$17K Buy
629
+467
+288% +$11K ﹤0.01% 5664
2020
Q1
$3K Sell
162
-510
-76% -$11.2K ﹤0.01% 6236
2019
Q4
$18K Buy
672
+572
+572% +$11.4K ﹤0.01% 5914
2019
Q3
$2K Hold
100
﹤0.01% 6338
2019
Q2
$3K Hold
100
﹤0.01% 6516
2019
Q1
$3K Hold
100
﹤0.01% 6471
2018
Q4
$2K Sell
100
-173
-63% -$4.57K ﹤0.01% 6498
2018
Q3
$9K Buy
273
+96
+54% +$3.14K ﹤0.01% 6048
2018
Q2
$7K Buy
177
+77
+77% +$2.49K ﹤0.01% 5958
2018
Q1
$3K Buy
100
+90
+900% +$3.03K ﹤0.01% 6072
2017
Q4
$0 Buy
+10
New +$254 ﹤0.01% 7030

Other funds holding ALBO

Royal Bank of Canada's ALBO Position: Q1 2023 in Review

Royal Bank of Canada sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 2,397 shares — an estimated $51K sold.

Royal Bank of Canada first reported a position in ALBO in Q4 2017 and held it in 21 quarters. The position peaked at $87K in Q4 2021. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.

  • Royal Bank of Canada reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
  • Royal Bank of Canada sold 2,397 Albireo Pharma Inc shares in Q1 2023, an estimated $51K.
  • Royal Bank of Canada first reported a position in Albireo Pharma Inc in Q4 2017 and held it in 21 quarters.
  • Royal Bank of Canada's Albireo Pharma Inc position peaked at $87K in Q4 2021.
  • 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.

Based on Royal Bank of Canada's 13F filing for Q1 2023, filed 15 May 2023.